argenx (ARGX) Stock Forecast & Price Target

Argenx demonstrates a positive financial outlook due to its strong revenue growth, as reflected in its impressive first-half 2025 performance, with revenues reaching $790 million in Q1 and $949 million in Q2, marking year-over-year increases of 98% and 97%, respectively. The adoption of the pre-filled syringe format for Vyvgart is contributing to this growth by expanding the prescriber base and driving increased patient usage in both generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Additionally, the company has potential for further expansion with ongoing developments in its pipeline, including promising Phase Ib trial results for ARGX-119, which are paving the way toward a registrational Phase III trial in 2026.

Argenx's stock outlook is negatively impacted by several key risks, including the potential for lower-than-expected sales growth of its lead product, Vyvgart, amid increasing competition and macroeconomic challenges such as inflation and foreign exchange fluctuations. Additionally, there are inherent uncertainties associated with ongoing clinical trials for efgartigimod and empasiprubart, including the possibility of unforeseen safety signals or regulatory setbacks that could hinder product approvals or market acceptance. These factors collectively contribute to a cautious stance on the company's ability to capitalize on its growing pipeline and advancements in therapy options for rare autoimmune diseases.